New research may lead to earlier Alzheimer's treatment
When Ken Roberts was diagnosed with Alzheimer’s Disease in September 2006, he was shocked. At age 72, he didn’t feel he was functioning outside of what his age should dictate. On the urging of a close friend, Roberts submitted to a five-hour evaluation at his primary care clinic. At the time, it is probable that Roberts was between three and four years into the disease’s progression. That is the average amount of time the illness goes unnoticed in patients, according to the Alzheimer’s Association. The problem with diagnosing the disease lies in the fact that symptoms for it are closely related to those of natural aging.
If a new study being conducted by researchers at the University of Kansas and McGill University in Montreal goes according to plan, Alzheimer’s may be diagnosed earlier by evaluating a word-recognition task and brain wave activity.
The idea for the research came from Nancy Azevedo, a graduate student at the Canadian university. During some routine testing, she noticed certain deficits among Alzheimer’s patients in a lexical decision task. The task was straight forward. It asked participants to evaluate strings of letters, some of which formed English words, and others that formed non-words.
“I noticed as I was compiling all of the data that they kept making all these mistakes with the non-words,” Azevedo said. “I couldn’t figure out why they were doing so much worse on this particular data.”
This observation led Azevedo to her research idea, which looks at language deficits and corresponding brain wave activities in hopes of finding an early marker for the fatal neurological disease.
Ruthann Atchley, a KU professor of psychology, worked closely with Azevedo to develop a method for testing the research hypothesis.
“What we want to do,” Atchley said. “is see if we can find some subtle effects of language that are disrupted very early on in the progression of the disease.”
The implications of finding an early marker for diagnosing Alzheimer’s Disease are numerous. An early diagnosis could lead to earlier treatment for the illness, which is the seventh leading cause of death in the US, according to the Alzheimer’s Association. It would also help prolong the lives of patients diagnosed in the early stages.
As it stands now, more than five million people in the US are living with Alzheimer’s. In the Kansas City area, there are approximately 25,000 people living with the disease. Michelle Niedens, the education director for the Alzheimer’s Association’s Heart of America chapter, said the average age of an individual with the disease is 65 years, with one in ten individuals of that age being diagnosed with the illness. Atchley said that early treatment could help those living with the illness enjoy a better life.
“If you can diagnose the disorder very early on and you intervene with drug therapy, the overall duration of life, of a good quality life, can be drastically extended,” Atchley said.
The study is in its preliminary stages, but looks to collect most of its data next year. The preliminary testing will consist of about 60 participants, 20 in each of three different groups. Each group comprises people with general cognitive impairments, mild-level Alzheimer’s and control conditions. If the early study shows promise, the range and number of participants will expand, and the likelihood of grant money being awarded will increase as well.
“This doesn’t just give us an early marker, which is worth it in and of itself,” Atchley said. “It also tells us something about the underlying cognition associated with Alzheimer’s disease.
Niedens agreed that the use of medication in the earlier stages of the illness is beneficial. She said that although there is some controversial research being conducted, most function-based studies confirm that the medication is indeed helpful.
“Those that get diagnosed very early now, I really believe they may benefit from the next generation of medication,” Niedens said. “Although a cure may still be some way down the road.”
Niedens said that medication given to early-stage Alzheimer’s patients is one of the most important tools in their mental stability. She said that the earlier the disease is diagnosed, the more hope it gives the individuals who are affected.
“Hope is far more than a cure,” Niedens said. “It’s lots of things. They are able to adapt their lives in meaningful ways.”
The research, if supported by early testing, will continue for as long as it is useful in the biomedical world. If successful, the study would also lend itself to testing for new Alzheimer’s drugs that may come on the market. The study would allow researches and doctors to evaluate the effectiveness of new drugs much quicker than is now possible.
Ken Roberts is content for now to keep taking the pills that his doctor prescribes. He said he hopes he will survive the disease until something new comes out to help fight it. He said it is all he and anyone with the disease can really do.
“I hope that in the next few years new medications will come out to stop the disease at whatever stage you’re at,” Roberts said. “For now, whatever the doctors tell us to take, we’re going to take it. We can’t afford to stop taking them. We can’t afford to take that chance.”



Phase Array Radar
The Lunte Research Group minimized the micro ships to the size of student IDs.
David Fischer, researcher in Lunte group, runs blood throughCapillary Electrophoresis System.




The research collected from the tagged butterflies has a benefit for ecologists as well. As Monarch Watch continues to accumulate years and years of data on the migration and population changes, the ecologists are able to correlate population fluctuations to ecological events such as climate change, habitat change and other environmental factors. This, in return, helps ecologists understand how these environmental changes affect general and specific populations over a long period of time.





Taryn Bagby, Kansas City, Mo., graduate student
Lab mouse infected with different cancers